NCT06525155View on ClinicalTrials.gov

Effect GnRH Agonist Administration in Endometriosis Cyst Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Endometriosis
Interventions
DRUG

Triptorelin Embonate

Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12

DRUG

Triptorelin Embonate

Treatment 2: 3.75 mg once after surgery at week-12

Trial Locations (1)

10410

RECRUITING

Department of Obstetrics and Gynecology Central Army Hospital Gatot Soebroto, Jakarta

Sponsors

Collaborators (1)

Dexa Medica Group
All Listed Sponsors
collaborator

Dexa Medica Group

INDUSTRY

lead

Rumah Sakit Pusat Angkatan Darat Gatot Soebroto

OTHER

NCT06525155 - Effect GnRH Agonist Administration in Endometriosis Cyst Patients | Biotech Hunter | Biotech Hunter